Shire's new dry-eye approval means it's time for an Allergan showdown


Shire ($SHPG) has the approval it’s been waiting for--and the label it wanted, too.

Late Monday, the FDA green-lighted dry-eye candidate lifitegrast, to be marketed under the brand name Xiidra. And the go-ahead is for both symptoms and signs of the condition--a label that Evercore ISI analyst Umer Raffat said “reads favorably for lifitegrast’s perception in the marketplace” as it faces down rival Restasis from Allergan ($AGN).

The med has taken longer to get to this point than Shire once hoped. Back in October, U.S. regulators handed down a rejection for the Dublin drugmaker, asking for an additional study and more product quality before they would bestow their favor. Shire was quick to meet their requests, though, rounding up positive data that dropped one week after the setback and turning right around with January resubmission.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Now, it’ll get a shot at a market that Bernstein analyst Ronny Gal expects to grow to close to $2 billion, he wrote in a Tuesday investor note. And it’ll also get a shot at stealing share from Restasis, an Allergan blockbuster he expects to decline from $1.3 billion to $900 million in 2020.

The reason? Restasis lacks Xiidra’s full dry eye label; it’s indicated only for “tear production.” That difference will buoy Xiidra in the marketplace, Raffat wrote in a Monday note to clients, and it could also help Shire make a case for pricing the newcomer at a premium to its nemesis.

But Allergan investors needn’t fret. “The key point regarding the competitive matchup is that it will likely be a stable oligopoly,” Gal wrote, noting that while Shire has the label advantage--plus a shorter onset of action--Allergan “enjoys the power of incumbency,” including contracts, sales and an established patient pool.

And even if Xiidra does grab some Restasis volume--say, 30% over time, Raffat estimates--Allergan may be able to offset about 10% to 15% of the top through a series of price increases, he figures.

- read Shire's release

Related Articles:
Allergan's Restasis defense stumbles at FDA as Shire loads up lifitegrast assault
Allergan pooh-poohs threat from Shire's prospective dry-eye drug
Shire's back on track with its dry-eye threat to Allergan's Restasis
Shire's eye drug setback gives Allergan's Restasis a temporary reprieve

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.